Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM, diagnosed at least 6 weeks prior to visit 1, who have had no treatment with oral antidiabetic agents for at least 12 weeks prior to study entry (visit 1) and no treatment with oral antidiabetic agents at any time in the past for \> 3 consecutive months~* \>/= 18 years~* Body mass index in the range of 22-35 kg/m2~* HbA1c \</=7.5%~Exclusion Criteria:~* Type 1 diabetes~* Acute metabolic diabetic complications~* Evidence of significant diabetic complications~* Insulin treatment within the past 6 months~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).